Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
Åkerblom A, Oldgren J, Latva-Rasku A, Johansson L, Lisovskaja V, Karlsson C, Oscarsson J, Nuutila P. Åkerblom A, et al. Among authors: johansson l. Ups J Med Sci. 2019 Jan;124(1):59-64. doi: 10.1080/03009734.2018.1515281. Epub 2019 Jan 8. Ups J Med Sci. 2019. PMID: 30618324 Free PMC article. Clinical Trial.
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtimäki T, Saltevo J, Kirjavainen AK, Saunavaara V, Iozzo P, Johansson L, Oscarsson J, Hannukainen JC, Nuutila P. Latva-Rasku A, et al. Among authors: johansson l. Diabetes Care. 2019 May;42(5):931-937. doi: 10.2337/dc18-1569. Epub 2019 Mar 18. Diabetes Care. 2019. PMID: 30885955 Free article. Clinical Trial.
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB, Risérus U, Lind L, Oscarsson J. Eriksson JW, et al. Among authors: johansson l. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3. Diabetologia. 2018. PMID: 29971527 Free PMC article. Clinical Trial.
Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
Oscarsson J, Önnerhag K, Risérus U, Sundén M, Johansson L, Jansson PA, Moris L, Nilsson PM, Eriksson JW, Lind L. Oscarsson J, et al. Among authors: johansson l. J Clin Lipidol. 2018 Nov-Dec;12(6):1390-1403.e4. doi: 10.1016/j.jacl.2018.08.003. Epub 2018 Aug 10. J Clin Lipidol. 2018. PMID: 30197273 Free article. Clinical Trial.
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Frías JP, Maaske J, Suchower L, Johansson L, Hockings PD, Iqbal N, Wilding JPH. Frías JP, et al. Among authors: johansson l. Diabetes Obes Metab. 2022 Jan;24(1):61-71. doi: 10.1111/dom.14548. Epub 2021 Sep 28. Diabetes Obes Metab. 2022. PMID: 34514692 Free PMC article. Clinical Trial.
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Bolinder J, et al. Among authors: johansson l. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11. J Clin Endocrinol Metab. 2012. PMID: 22238392 Clinical Trial.
1,561 results